Based on the outstanding expertise and rich experience, Creative Biolabs has specially developed a system approach of TCR generation and optimization for TCR development.
Although T cells have the capacity to eradicate diseased cells, tumors still present considerable challenges that render T cells ineffectual. Cancer cells often make themselves almost ‘invisible’ to the immune system, and they sculpt a microenvironment that suppresses T cell activity, survival and migration. Genetic engineering of T cells can be used therapeutically to overcome these challenges. Cancer-targeted adoptive T cell therapy with genetically engineered α and β T cell receptors (TCRs) has resulted in encouraging responses in some patients. Broadening this approach to a large array of malignancies requires targeting more widely expressed tumor-associated antigens (TAAs).
Naïve T cells are migratory cells that continuously recirculate between blood and lymphoid tissues. Antigen-specific stimulation of T cells within the lymph nodes reprograms the trafficking properties of T cells by inducing a specific set of adhesion molecules and chemokine receptors on their surface which allow these activated and effector T cells to effectively and specifically home to extra lymphoid organs. The observations of organ-specific homing of T cells initiate the development of therapeutic strategies targeting adhesion receptors for organ-specific inhibition of chronic inflammation. As most adhesion receptors have additional immune functions besides mediating leukocyte trafficking, these drugs may have additional immunomodulatory effects. Creative Biolabs provides a preclinical in vivo approach to directly visualize the therapeutic efficacy of TCR in inhibiting T cell homing to a certain organ.
Fig.1 T Cell Trafficking Between Compartments
Creative Biolabs has the capability to enable you to free up your time for core work and project. Our service can be designed to meet your special needs if you have any requirements. If you are interested in our service, please contact us by E-mail and our team will get back to you as soon as possible.
Coisne C, et al. Preclinical testing of strategies for therapeutic targeting of human T-cell trafficking in vivo. Springer Protocols, 2010 (616): 81-268.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy product with the complete TCR complex without HLA matching dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE